Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00792415
NCT00792415WithdrawnNot Applicable

Validation of a Pediatric Abstinence Syndrome Scoring Tool Utilizing a Standardized Hospital-Based Guideline for Iatrogenic Opioid Dependence

Banner Health1 site in 1 country75 target enrollmentStarted: November 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Enrollment
75
Locations
1
Primary Endpoint
Total scores of abstinence syndrome symptoms
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to assess the validity and reliability of an abstinence syndrome assessment tool used in pediatric patients with iatrogenic opioid dependence.

Detailed Description

None available.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Other

Eligibility Criteria

Ages
2 Weeks to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Pediatric Intensive Care Unit patients ages 2 weeks to 18 years
  • •Patients receiving continuous opioid infusions for 5 days (at least 120 hours) or more

Exclusion Criteria

  • •Attending discretion
  • •Patients with deterioration of medical status requiring interventions of pain control, surgery, sedation, or re-intubation

Outcomes

Primary Outcomes

Total scores of abstinence syndrome symptoms

Time Frame: Up to 23 days

None available - PI no longer with Banner

Secondary Outcomes

  • Expert opinion on abstinence syndrome(Up to 23 days)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
Vaping and Smoking Withdrawal Project
NCT05772845State University of New York at Buffalo370
Completed
Phase 2
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic DermatitisAtopic Dermatitis
NCT01232543Fougera Pharmaceuticals Inc.114
Completed
Not Applicable
Evaluation of TYR Sphere in FranceTyrosinemiaAKU
NCT04761588Vitaflo International, Ltd14
Completed
Phase 2
Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent WomenNarcotic AddictionNeonatal Abstinence Syndrome
NCT01965704Stanford University196
Active, not recruiting
Phase 4
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary TherapyNeonatal Abstinence Syndrome
NCT03092011The Cooper Health System69